Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
This new microcast provides a brief audio tour around Scrip’s Five Must-Know Things, in this episode for the week ended 3 July.
On the agenda this time are coronavirus vaccines, progress in NASH, the pricing of a new epilepsy drug and one multinational's efforts to assure investors of R&D progress.
Stories mentioned in this episode:
(Also see "Pfizer CEO Bourla Wants Profit From COVID-19 Vaccine" - Scrip, 30 Jun, 2020.)
(Also see "CanSino Coronavirus Vaccine Approved For Military Use In China" - Scrip, 29 Jun, 2020.)
(Also see "Intercept’s CRL Just Continues Upheaval In NASH" - Scrip, 29 Jun, 2020.)
(Also see "Zogenix Risks Fintepla Uptake With Dravet Drug’s High Price" - Scrip, 28 Jun, 2020.)
(Also see "No Looking Back For Sanofi In R&D Turnaround Quest" - Scrip, 26 Jun, 2020.)